Cargando…

Cardiac Troponin Biosensor Designs: Current Developments and Remaining Challenges

Acute myocardial infarction (AMI) is considered as one of the main causes of death, threating human lives for decades. Currently, its diagnosis relies on electrocardiography (ECG), which has been proven to be insufficient. In this context, the efficient detection of cardiac biomarkers was proposed t...

Descripción completa

Detalles Bibliográficos
Autores principales: Campu, Andreea, Muresan, Ilinca, Craciun, Ana-Maria, Cainap, Simona, Astilean, Simion, Focsan, Monica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318943/
https://www.ncbi.nlm.nih.gov/pubmed/35887073
http://dx.doi.org/10.3390/ijms23147728
_version_ 1784755427516350464
author Campu, Andreea
Muresan, Ilinca
Craciun, Ana-Maria
Cainap, Simona
Astilean, Simion
Focsan, Monica
author_facet Campu, Andreea
Muresan, Ilinca
Craciun, Ana-Maria
Cainap, Simona
Astilean, Simion
Focsan, Monica
author_sort Campu, Andreea
collection PubMed
description Acute myocardial infarction (AMI) is considered as one of the main causes of death, threating human lives for decades. Currently, its diagnosis relies on electrocardiography (ECG), which has been proven to be insufficient. In this context, the efficient detection of cardiac biomarkers was proposed to overcome the limitations of ECG. In particular, the measurement of troponins, specifically cardiac troponin I (cTnI) and cardiac troponin T (cTnT), has proven to be superior in terms of sensitivity and specificity in the diagnosis of myocardial damage. As one of the most life-threatening conditions, specific and sensitive investigation methods that are fast, universally available, and cost-efficient to allow for early initiation of evidence-based, living-saving treatment are desired. In this review, we aim to present and discuss the major breakthroughs made in the development of cTnI and cTnT specific biosensor designs and analytical tools, highlighting the achieved progress as well as the remaining challenges to reach the technological goal of simple, specific, cheap, and portable testing chips for the rapid and efficient on-site detection of cardiac cTnI/cTnT biomarkers in order to diagnose and treat cardiovascular diseases at an incipient stage.
format Online
Article
Text
id pubmed-9318943
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93189432022-07-27 Cardiac Troponin Biosensor Designs: Current Developments and Remaining Challenges Campu, Andreea Muresan, Ilinca Craciun, Ana-Maria Cainap, Simona Astilean, Simion Focsan, Monica Int J Mol Sci Review Acute myocardial infarction (AMI) is considered as one of the main causes of death, threating human lives for decades. Currently, its diagnosis relies on electrocardiography (ECG), which has been proven to be insufficient. In this context, the efficient detection of cardiac biomarkers was proposed to overcome the limitations of ECG. In particular, the measurement of troponins, specifically cardiac troponin I (cTnI) and cardiac troponin T (cTnT), has proven to be superior in terms of sensitivity and specificity in the diagnosis of myocardial damage. As one of the most life-threatening conditions, specific and sensitive investigation methods that are fast, universally available, and cost-efficient to allow for early initiation of evidence-based, living-saving treatment are desired. In this review, we aim to present and discuss the major breakthroughs made in the development of cTnI and cTnT specific biosensor designs and analytical tools, highlighting the achieved progress as well as the remaining challenges to reach the technological goal of simple, specific, cheap, and portable testing chips for the rapid and efficient on-site detection of cardiac cTnI/cTnT biomarkers in order to diagnose and treat cardiovascular diseases at an incipient stage. MDPI 2022-07-13 /pmc/articles/PMC9318943/ /pubmed/35887073 http://dx.doi.org/10.3390/ijms23147728 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Campu, Andreea
Muresan, Ilinca
Craciun, Ana-Maria
Cainap, Simona
Astilean, Simion
Focsan, Monica
Cardiac Troponin Biosensor Designs: Current Developments and Remaining Challenges
title Cardiac Troponin Biosensor Designs: Current Developments and Remaining Challenges
title_full Cardiac Troponin Biosensor Designs: Current Developments and Remaining Challenges
title_fullStr Cardiac Troponin Biosensor Designs: Current Developments and Remaining Challenges
title_full_unstemmed Cardiac Troponin Biosensor Designs: Current Developments and Remaining Challenges
title_short Cardiac Troponin Biosensor Designs: Current Developments and Remaining Challenges
title_sort cardiac troponin biosensor designs: current developments and remaining challenges
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318943/
https://www.ncbi.nlm.nih.gov/pubmed/35887073
http://dx.doi.org/10.3390/ijms23147728
work_keys_str_mv AT campuandreea cardiactroponinbiosensordesignscurrentdevelopmentsandremainingchallenges
AT muresanilinca cardiactroponinbiosensordesignscurrentdevelopmentsandremainingchallenges
AT craciunanamaria cardiactroponinbiosensordesignscurrentdevelopmentsandremainingchallenges
AT cainapsimona cardiactroponinbiosensordesignscurrentdevelopmentsandremainingchallenges
AT astileansimion cardiactroponinbiosensordesignscurrentdevelopmentsandremainingchallenges
AT focsanmonica cardiactroponinbiosensordesignscurrentdevelopmentsandremainingchallenges